Rapamycin fed late in life extends lifespan in genetically heterogeneous mice (original) (raw)

Nature volume 460, pages 392–395 (2009)Cite this article

This article has been updated

Abstract

Inhibition of the TOR signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and fruitflies1,2,3,4,5; however, whether inhibition of mTOR signalling can extend lifespan in a mammalian species was unknown. Here we report that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females, based on an interim analysis conducted near the median survival point. Rapamycin may extend lifespan by postponing death from cancer, by retarding mechanisms of ageing, or both. To our knowledge, these are the first results to demonstrate a role for mTOR signalling in the regulation of mammalian lifespan, as well as pharmacological extension of lifespan in both genders. These findings have implications for further development of interventions targeting mTOR for the treatment and prevention of age-related diseases.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Change history

A present address author affiliation was added to C.S.C. on 16 July 2009.

References

  1. Kaeberlein, M. et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 310, 1193–1196 (2005)
    Article ADS CAS Google Scholar
  2. Powers, R. W., Kaeberlein, M., Caldwell, S. D., Kennedy, B. K. & Fields, S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 20, 174–184 (2006)
    Article CAS Google Scholar
  3. Jia, K., Chen, D. & Riddle, D. L. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 131, 3897–3906 (2004)
    Article CAS Google Scholar
  4. Kapahi, P. et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14, 885–890 (2004)
    Article CAS Google Scholar
  5. Vellai, T. et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426, 620 (2003)
    Article ADS CAS Google Scholar
  6. Kohn, R. R. Principles of Mammalian Aging 2nd edn 151 (Prentice-Hall, 1978)
    Google Scholar
  7. Miller, R. A. Extending life: scientific prospects and political obstacles. Milbank Q. 80, 155–174 (2002)
    Article Google Scholar
  8. Olshansky, S. J., Perry, D., Miller, R. A. & Butler, R. N. In pursuit of the longevity dividend. Scientist 20, 28–35 (2006)
    Google Scholar
  9. Schneider, E. L. & Miller, R. A. in Brockelhurst's Textbook of Geriatric Medicine (eds Tallis, R., Fillit, H. & Brockelhurst, J. C.) 193–199 (Churchill Livingstone, 1998)
    Google Scholar
  10. Archer, J. R. & Harrison, D. E. l-deprenyl treatment in aged mice slightly increases lifespans, and greatly reduces fecundity by aged males. J Gerontol. Biol. Sci. 51A, B448–B453 (1996)
    Article CAS Google Scholar
  11. Schneider, E. L. & Reed, J. D. Life extension. N. Engl. J. Med. 312, 1159–1168 (1985)
    Article CAS Google Scholar
  12. Phelan, J. P. & Austad, S. N. Selecting animal models of human aging. Inbred strains often exhibit less biological uniformity than F1 hybrids. J. Gerontol. 49, B1–B11 (1994)
    Article CAS Google Scholar
  13. Klebanov, S. E. et al. Maximum life spans in mice are extended by wild strain alleles. Exp. Biol. Med. 226, 854–859 (2001)
    Article CAS Google Scholar
  14. Flurkey, K., Currer, J. M. & Harrison, D. E. in The Mouse in Biomedical Research 2nd edn, Vol. III (eds Fox, J. G. et al.) 637–672 (Academic, 2007)
    Book Google Scholar
  15. Miller, R. A. et al. An aging interventions testing program: study design and interim report. Aging Cell 6, 565–575 (2007)
    Article ADS CAS Google Scholar
  16. Nadon, N. L. et al. Design of aging intervention studies: the NIA interventions testing program. AGE 30, 187–199 (2008)
    Article CAS Google Scholar
  17. Strong, R. et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 7, 641–650 (2008)
    Article CAS Google Scholar
  18. Roderick, T. H. Selection for radiation resistance in mice. Genetics 48, 205–216 (1963)
    CAS PubMed PubMed Central Google Scholar
  19. Wang, C., Li, Q., Redden, D. T., Weindruch, R. D. & Allison, B. Statistical methods for testing effects on “maximum lifespan”. Mech. Ageing Dev. 125, 629–632 (2004)
    Article Google Scholar
  20. Petroulakis, E., Mamane, Y., Le Bacquer, O., Shahbazian, D. & Sonenberg, N. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 96 (Suppl.). R11–R15 (2007)
    Article Google Scholar
  21. Masoro, E. J. Overview of caloric restriction and ageing. Mech. Ageing Dev. 126, 913–922 (2005)
    Article CAS Google Scholar
  22. Sharp, Z. D. & Bartke, A. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J. Gerontol. A 60, 293–300 (2005)
    Article Google Scholar
  23. Hsieh, C. C. & Papaconstantinou, J. Akt/PKB and p38 MAPK signaling, translational initiation and longevity in Snell dwarf mouse livers. Mech. Ageing Dev. 125, 785–798 (2004)
    Article CAS Google Scholar
  24. Dhahbi, J. M. et al. Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proc. Natl Acad. Sci. USA 101, 5524–5529 (2004)
    Article ADS CAS Google Scholar
  25. Garber, K. Rapamycin’s resurrection: a new way to target the cancer cell cycle. J. Natl Cancer Inst. 93, 1517–1519 (2001)
    Article CAS Google Scholar
  26. Lorberg, A. & Hall, M. N. TOR: the first 10 years. Curr. Top. Microbiol. Immunol. 279, 1–18 (2004)
    CAS PubMed Google Scholar
  27. Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471–484 (2006)
    Article CAS Google Scholar
  28. Reiling, J. H. & Sabatini, D. M. Stress and mTORture signaling. Oncogene 25, 6373–6383 (2006)
    Article CAS Google Scholar
  29. Sonenberg, N. & Hinnebusch, A. G. New modes of translational control in development, behavior, and disease. Mol. Cell 28, 721–729 (2007)
    Article CAS Google Scholar
  30. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976)
    Article CAS Google Scholar

Download references

Acknowledgements

This work was supported by NIA grants AG022303 (R.A.M.), AG025707 and AG022308 (D.E.H.), AG022307 (R.S.) and AG13319 (J.F.N. and R.S.), and the Department of Veterans Affairs (R.A.M. and R.S.) and DoD W81XWH-07-1-0605 (Z.D.S.). We wish to thank P. J. Krason, P. J. Harrison, E. Adler, V. Diaz, J. Sewald, L. Burmeister, B. Kohler, M. Han, M. Lauderdale and D. Jones for reliable technical assistance, S. Pletcher and A. Galecki for statistical assistance, and H. Warner and S. N. Austad for scientific counsel.

Author Contributions D.E.H., R.S. and R.A.M. serve as the principal investigators at the three collaborating institutions; they were responsible for project design, supervision of technical personnel, interpretation of results, and preparation of manuscript drafts. Z.D.S. proposed rapamycin for the study, and was responsible for the measures of mTOR function. J.F.N. and K. Flurkey provided advice on experimental design and interpretation, and comments on the manuscript. Lab manager C.M.A. provided advice, and supervised laboratory procedures and data collection at The Jackson Laboratory site. N.L.N. served as the project officer for the National Institute on Aging, and contributed to program development, experimental design and analysis. J.E.W. conducted and helped interpret the necropsy analyses. K. Frenkel recommended CAPE for the study, and advised on dose and route of administration. C.S.C. and M.P. recommended enalapril for the study, and advised on dose and route of administration. M.A.J. was responsible for the pharmacological analyses. E.F. supervised and conducted laboratory procedures and data collection at the University of Texas site.

Author information

Author notes

  1. Christy S. Carter & Marco Pahor
    Present address: Present address: Department of Aging and Geriatric Research, College of Medicine, Institute on Aging, University of Florida, Gainesville, Florida 32611, USA.,
  2. David E. Harrison, Randy Strong and Richard A. Miller: These authors contributed equally to this work.

Authors and Affiliations

  1. The Jackson Laboratory, Bar Harbor, Maine 04609, USA,
    David E. Harrison, Clinton M. Astle & Kevin Flurkey
  2. Department of Pharmacology, Geriatric Research, Education and Clinical Center and Research Service, South Texas Veterans Health Care System, and Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, Texas 78229, USA,
    Randy Strong & Elizabeth Fernandez
  3. Institute of Biotechnology/Department of Molecular Medicine, and Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, Texas 78245, USA,
    Zelton Dave Sharp
  4. Department of Physiology and Barshop Institute for Longevity and Aging Studies at The University of Texas Health Science Center at San Antonio, Texas 78229, USA,
    James F. Nelson
  5. Division of Aging Biology, National Institute on Aging, Bethesda, Maryland 20892, USA,
    Nancy L. Nadon
  6. Unit for Laboratory Animal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109-2200, USA,
    J. Erby Wilkinson
  7. Environmental Medicine, NY University School of Medicine, New York 10016, USA
    Krystyna Frenkel
  8. Department of Internal Medicine: Section on Gerontology and Geriatrics Winston-Salem, Wake Forest University School of Medicine, North Carolina 27157, USA,
    Christy S. Carter & Marco Pahor
  9. Department of Psychiatry, The University of Texas Health Science Center at San Antonio, Texas 78229, USA,
    Martin A. Javors
  10. Department of Pathology and Geriatrics Center, University of Michigan, and Ann Arbor VA Medical Center, Ann Arbor, Michigan 48109-2200, USA,
    Richard A. Miller

Authors

  1. David E. Harrison
    You can also search for this author inPubMed Google Scholar
  2. Randy Strong
    You can also search for this author inPubMed Google Scholar
  3. Zelton Dave Sharp
    You can also search for this author inPubMed Google Scholar
  4. James F. Nelson
    You can also search for this author inPubMed Google Scholar
  5. Clinton M. Astle
    You can also search for this author inPubMed Google Scholar
  6. Kevin Flurkey
    You can also search for this author inPubMed Google Scholar
  7. Nancy L. Nadon
    You can also search for this author inPubMed Google Scholar
  8. J. Erby Wilkinson
    You can also search for this author inPubMed Google Scholar
  9. Krystyna Frenkel
    You can also search for this author inPubMed Google Scholar
  10. Christy S. Carter
    You can also search for this author inPubMed Google Scholar
  11. Marco Pahor
    You can also search for this author inPubMed Google Scholar
  12. Martin A. Javors
    You can also search for this author inPubMed Google Scholar
  13. Elizabeth Fernandez
    You can also search for this author inPubMed Google Scholar
  14. Richard A. Miller
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toDavid E. Harrison.

Supplementary information

Supplementary Information

This file contains Supplementary Methods, Supplementary Tables S1-S2 and Supplementary Figure 1. (PDF 542 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Harrison, D., Strong, R., Sharp, Z. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.Nature 460, 392–395 (2009). https://doi.org/10.1038/nature08221

Download citation

Editorial Summary

Rapamycin for a longer life?

The antitumour drug rapamycin targets TOR, a kinase that is part of the PI3K–AKT–mTOR cascade, involved in regulating protein translation, cell growth and autophagy. Reducing TOR function is known to extend the life of yeast, worms and flies. Now experiments replicated in three different laboratories demonstrate that rapamycin, fed to male and female mice in a dose that substantially inhibits TOR signalling, can extend their median and maximal lifespan by up to 14%. This life extension was observed in mice fed rapamycin from 270 days of age and also at a late stage in their life, from age 600 days. These findings point to the TOR pathway as a critical point in the control of ageing in mammals and in the pathogenesis of late-life illnesses.

Associated content